Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients (NCT01189409) | Clinical Trial Compass
TerminatedPhase 4
Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients
Stopped: This study was terminated based on results of interim analysis.
Canada70 participantsStarted 2010-06
Plain-language summary
This is a study to compare the efficacy and tolerability of two laxatives for treatment of opioid-induced constipation in adult outpatients with cancer treated at the British Columbia Cancer Pain and Symptom Management/Palliative Care clinics. Each participating patient will be randomly assigned to one of two treatment groups.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adult patient (18 years and above) with diagnosis of cancer.
✓. Patient requires treatment or prevention of constipation.
✓. Patient is able to communicate effectively with staff.
✓. Expected prognosis more than 12 weeks.
✓. On or starting opioid therapy
Exclusion criteria
✕. Patient unable to take oral medication.
✕. Allergy or previous intolerance to PEG or sennosides.
✕. Lactose intolerant.
✕. Contraindication to PEG or sennosides.
✕. Known or suspected bowel obstruction or ileus.
✕. Colostomy or ileostomy.
✕
What they're measuring
1
Bowel Performance Scale (BPS)
Timeframe: Last 18 days of each 21 day study period